Mapping Existing Drugs to Aging Hallmarks: A Network Medicine Breakthrough
Some links in this article are affiliate links. As an Amazon Associate and partner of other programs, Vitalheros may earn a commission from qualifying purchases, at no extra cost to you. This never influences our editorial coverage.
The quest to understand and ultimately modulate the aging process has long captivated humanity. While the dream of a ‘longevity pill’ might sound like science fiction, rigorous scientific inquiry is steadily bringing us closer to practical interventions. A groundbreaking study from Northeastern University and Harvard, recently published in Nature Aging, offers a sophisticated new method to identify existing drugs with the potential to slow aspects of aging by leveraging the intricate web of human biology.
This research introduces a network-based approach to predict which approved medications might influence the multifaceted biological processes that drive aging. By mapping thousands of genes and drug targets onto the human ‘interactome’ – the vast network of protein interactions within our cells – scientists are now better equipped to uncover hidden longevity signals in drugs already on pharmacy shelves.
The Complex Web of Aging and Drug Discovery
Aging is not a simple, linear process; it’s a complex, multifactorial phenomenon involving thousands of genes and intricate biological pathways. This inherent complexity presents significant hurdles for drug discovery. Traditionally, developing a new drug from scratch to target aging would entail decades of research, preclinical testing, and extensive human trials. Furthermore, regulatory frameworks are primarily designed for single-disease indications, making it challenging to approve a drug specifically for ‘aging’ itself.
Yet, the landscape of medicine already boasts thousands of approved drugs, each meticulously studied for its effects on various diseases. What if some of these medications, perhaps serendipitously, also influence the rate of aging? The concept of drug repurposing – finding new uses for existing drugs – offers an attractive shortcut, potentially accelerating the availability of anti-aging interventions. The challenge, as Albert-László Barabási, a Distinguished University Professor of Physics at Northeastern and a leader of the study, noted, is “figuring out which drugs are worth testing.”
Network Medicine: A New Lens for Longevity
At the heart of this innovative study lies network medicine, a framework developed over more than fifteen years by the Barabási lab. This approach views the body’s proteins not as isolated entities but as interconnected nodes within a giant network, or ‘interactome.’ This network illustrates how proteins physically or functionally interact, forming a dynamic biological map.
In this framework, genes associated with a specific disease often cluster together into a ‘disease module’ within the interactome. Once such a module is identified, researchers can investigate which drugs have targets in the vicinity of this ‘neighborhood,’ making them candidates for perturbing the disease process. This method has previously yielded insights into conditions like asthma, heart disease, and even COVID-19.
The current study ingeniously applied this network medicine paradigm to the ‘Hallmarks of Aging,’ a widely accepted framework in geroscience that describes the fundamental biological processes that become disrupted with age. These hallmarks include critical features like DNA stability, cellular senescence, and intercellular communication. The premise was that each hallmark could be treated much like a disease module, allowing the same network-based machinery to be applied.
“You have genes related to aging by some definition or by some reasoning, but it feels like you just have a very big pile of genes related to aging,” explained Bnaya Gross, a postdoctoral researcher in Barabási’s lab and lead author of the study. “Networks allow us to organize them, saying, OK, it’s not just a pile of genes. They are connected to each other. They form some sort of organization. It’s not a random process.”
Mapping Genes and Drugs to Aging Hallmarks
The research began by curating data from the OpenGenes database, a comprehensive resource linking 2,358 genes to aging and longevity. Each gene was assigned a confidence level, indicating the strength of its association with mammalian lifespan extension. From this extensive list, 1,250 genes were successfully assigned to at least one of the established hallmarks of aging. Notably, many genes were found to be associated with multiple hallmarks, underscoring the interconnected nature of aging processes and the shared molecular machinery involved.
These 1,250 hallmark-associated genes were then mapped onto the human interactome, a vast network encompassing over 500,000 experimentally validated protein interactions. Next, the team examined 6,442 compounds from DrugBank, a public database of drug information. For each hallmark module, they measured each drug’s ‘network proximity’ – the average shortest-path distance between the drug’s protein targets and the nearest genes associated with that specific hallmark. Drugs whose targets were significantly closer than expected by chance were predicted to influence that hallmark.
However, proximity alone wasn’t enough. The researchers observed that some drugs, while proximal, could act in a detrimental direction, for instance, inducing rather than reducing cellular senescence. This highlighted the need for a more nuanced metric.
Introducing pAGE and the SHARP Pipeline
To address the issue of directionality, the researchers developed a novel metric they termed ‘pAGE.’ This metric, combined with network proximity, formed the basis of their ‘Systematic Hallmark-based Aging Repurposing Pipeline,’ or SHARP. The SHARP pipeline was designed not only to identify drugs that interact with aging hallmarks but also to predict whether those interactions are likely to be beneficial or detrimental.
The team rigorously validated SHARP against existing data from mammalian longevity studies. For instance, among the eight compounds known to increase mouse lifespan in the highly regarded Intervention Testing Program (ITP) trials and for which interactomic data was available, all demonstrated a positive pAGE for at least one hallmark. Conversely, less than half of the drugs that failed in the ITP trials showed such a positive pAGE score.
Further validation came from drugs currently undergoing human longevity trials, such as metformin and rapamycin. Out of 17 such compounds, 11 showed significant network proximity to at least one hallmark. Interestingly, aspirin was mapped to six hallmarks, and dasatinib to five, while rapamycin, a well-known longevity research compound, notably hit only one: intercellular communication. The method also successfully predicted outcomes for 10 compounds from a separate study whose results emerged after the SHARP predictions were made, providing a strong prospective test of its accuracy.
Uncovering Hidden Longevity Agents
Applying the SHARP pipeline across all hallmarks, the researchers identified 370 existing drugs that showed significant proximity to at least one aging hallmark. A particularly intriguing discovery was the identification of 83 ‘network drugs.’ These are compounds that do not directly target any known aging gene but instead influence a hallmark module through their broader impact on the network’s topology.
These ‘network drugs’ represent a significant breakthrough, as they would be entirely invisible to traditional drug discovery methods that focus solely on direct drug-target relationships. Their identification strongly underscores the power and unique advantage of the network medicine approach, revealing previously unrecognized therapeutic potential within existing pharmacopeias. The team also demonstrated that their predictions were mechanistically interpretable, providing insights into precisely how these drugs might exert their effects, as illustrated with an analysis of oxymetazoline, a common decongestant.
The Road Ahead: Potential and Caveats
This study marks a significant stride in geroscience, offering a rational, data-driven framework to accelerate the identification of promising anti-aging compounds from the vast repository of approved drugs. By moving beyond a ‘one gene, one drug, one disease’ paradigm, network medicine provides a holistic view of how drugs interact with the complex biological systems underpinning aging.
While the SHARP pipeline offers a powerful predictive tool, it is crucial to remember that these are predictions. The ultimate validation of any drug’s anti-aging potential still requires rigorous clinical trials in humans. This research, however, provides a much-needed roadmap, helping scientists prioritize which existing drugs are most promising for further investigation, potentially saving years and immense resources in the pursuit of interventions that could genuinely extend healthy human lifespan.
Explore more in our Longevity & Biohacking coverage.
🔬 Scientific Takeaway
A novel network medicine approach, the Systematic Hallmark-based Aging Repurposing Pipeline (SHARP), identifies existing drugs with potential anti-aging properties. By mapping drug targets to the Hallmarks of Aging within the human interactome, this method predicts beneficial interactions and uncovers 'network drugs' that act indirectly on aging pathways, offering a powerful tool for drug repurposing in geroscience.
Sources & References
Photo by Trnava University on Unsplash.
Medical Disclaimer: This article is AI-assisted and reviewed by the Vitalheros editorial team. It is provided for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Reviewed by The Vitalheros Editorial Team.
